McKesson Corporation awarded $900M IDIQ for pharmaceutical supplies to Indian Health Service

Contract Overview

Contract Amount: $9,000,000 ($9.0M)

Contractor: Mckesson Corporation

Awarding Agency: Department of Health and Human Services

Start Date: 2025-08-24

End Date: 2027-08-23

Contract Duration: 729 days

Daily Burn Rate: $12.3K/day

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: PHARMACEUTICAL SUPPLIES, PHARMACY PRIME VENDOR (IDIQ) PURCHASES FOR NSSC CUSTOMERS.

Place of Performance

Location: OKLAHOMA CITY, OKLAHOMA County, OKLAHOMA, 73114

State: Oklahoma Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $9.0 million to MCKESSON CORPORATION for work described as: PHARMACEUTICAL SUPPLIES, PHARMACY PRIME VENDOR (IDIQ) PURCHASES FOR NSSC CUSTOMERS. Key points: 1. This contract represents a significant portion of the Indian Health Service's pharmaceutical spending. 2. The firm-fixed-price structure provides cost certainty for the government. 3. The long duration of the contract (729 days) suggests a need for sustained supply. 4. The North American Industry Classification System (NAICS) code 325412 indicates a focus on pharmaceutical preparation manufacturing. 5. The contract's value is substantial, requiring careful monitoring of delivery orders. 6. The geographic scope appears to be national, serving NSSC customers.

Value Assessment

Rating: good

The contract value of $900 million over two years suggests a significant volume of pharmaceutical purchases. Benchmarking this against similar prime vendor contracts for federal healthcare providers is crucial. While specific unit costs are not provided, the firm-fixed-price nature aims to control overall expenditure. The scale of this award indicates McKesson's established position in supplying federal agencies.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, indicating that multiple qualified vendors had the opportunity to bid. This competitive process is expected to yield favorable pricing and terms for the government. The number of bidders is not specified, but the full and open nature suggests a robust competition.

Taxpayer Impact: Full and open competition generally leads to better price discovery and ensures that taxpayer dollars are used efficiently by fostering a competitive environment among suppliers.

Public Impact

Patients served by the Indian Health Service will benefit from a consistent and reliable supply of necessary pharmaceuticals. Healthcare providers within the IHS network will have access to a broad range of pharmaceutical products through this prime vendor. The contract supports the IHS's mission to provide comprehensive healthcare services to American Indians and Alaska Natives. The availability of these supplies is critical for the effective operation of IHS facilities nationwide.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for price increases on specific drugs over the contract term despite fixed pricing.
Dependence on a single prime vendor could create supply chain vulnerabilities if not managed proactively.
Ensuring equitable distribution of pharmaceuticals across all IHS facilities.

Positive Signals

The firm-fixed-price contract provides budget predictability.
Full and open competition suggests a competitive pricing environment.
The long-term nature of the IDIQ allows for streamlined ordering and delivery.

Sector Analysis

This contract falls within the pharmaceutical manufacturing and distribution sector, a critical component of the healthcare industry. The federal government is a major purchaser of pharmaceuticals, with significant spending directed through agencies like the Indian Health Service. This IDIQ award to McKesson, a large established player, reflects the market dynamics where a few key distributors serve the majority of federal healthcare needs. Comparable spending benchmarks would involve analyzing other large-scale pharmaceutical prime vendor contracts across different federal agencies.

Small Business Impact

The provided data indicates that small business participation is not a primary focus of this specific award, as the 'ss' (small business set-aside) field is false. However, McKesson, as the prime vendor, may engage small businesses for subcontracting opportunities related to pharmaceutical distribution or specialized services. The impact on the small business ecosystem would depend on the extent of such subcontracting arrangements.

Oversight & Accountability

Oversight for this contract will likely be managed by the Indian Health Service contracting officers and program managers. Accountability measures are embedded in the firm-fixed-price delivery order structure, requiring McKesson to meet specified delivery schedules and product quality standards. Transparency is facilitated through federal contract databases where award details are published. The Inspector General's office for the Department of Health and Human Services may conduct audits or investigations as deemed necessary.

Related Government Programs

Federal Supply Schedule (FSS) for Pharmaceuticals
Department of Veterans Affairs Pharmaceutical Contracts
TRICARE Pharmacy Program
National Institutes of Health (NIH) Research Grants

Risk Flags

Supply Chain Reliability
Price Volatility of Pharmaceuticals
Equitable Distribution Across Facilities
Contractor Performance Monitoring

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $9.0 million to MCKESSON CORPORATION. PHARMACEUTICAL SUPPLIES, PHARMACY PRIME VENDOR (IDIQ) PURCHASES FOR NSSC CUSTOMERS.

Who is the contractor on this award?

The obligated recipient is MCKESSON CORPORATION.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Indian Health Service).

What is the total obligated amount?

The obligated amount is $9.0 million.

What is the period of performance?

Start: 2025-08-24. End: 2027-08-23.

What is McKesson Corporation's track record with federal pharmaceutical contracts?

McKesson Corporation has a long and extensive history of serving as a prime vendor for pharmaceutical supplies to various U.S. federal agencies, including the Department of Defense, Department of Veterans Affairs, and the Indian Health Service. They are one of the largest pharmaceutical distributors in the United States and globally. Their track record typically involves managing complex supply chains, ensuring timely delivery of a wide array of medications, and adhering to stringent regulatory requirements. Past performance reviews and contract compliance data, often available through federal procurement databases, would provide more granular insights into their specific performance on previous IHS or similar contracts, including any past issues or commendations regarding delivery, quality, or pricing.

How does the $900 million value compare to historical IHS pharmaceutical spending?

The $900 million value for this two-year Indefinite Delivery/Indefinite Quantity (IDIQ) contract represents a substantial investment in pharmaceutical supplies for the Indian Health Service (IHS). To contextualize this, one would need to examine historical IHS pharmaceutical spending data. For instance, if previous annual pharmaceutical expenditures by the IHS have averaged between $400-$500 million, then this $900 million contract over two years aligns with or slightly increases that spending trend. If historical spending was significantly lower, it might indicate an expansion of services, increased drug costs, or a shift in procurement strategy. Analyzing the average annual value of prior prime vendor contracts for the IHS would provide a direct comparison point.

What are the primary risks associated with a sole-source or limited competition pharmaceutical contract of this magnitude?

While this contract is listed as 'full and open competition,' if it were sole-source or limited, the primary risks would include potential overpricing due to lack of competitive pressure, reduced innovation from the supplier, and increased vulnerability to supply chain disruptions if the single contractor faces issues. For a contract of this magnitude ($900 million), a sole-source award could mean taxpayers are not receiving the best possible value. Limited competition might still result in fewer bids than ideal, potentially leading to less aggressive pricing. The government would also have less leverage in negotiating terms and conditions. Therefore, the 'full and open' designation is a positive indicator mitigating these specific risks.

How effective is the prime vendor model for ensuring pharmaceutical availability in remote IHS facilities?

The prime vendor model, particularly an IDIQ contract like this, is generally considered an effective mechanism for ensuring pharmaceutical availability across a geographically dispersed healthcare system like the Indian Health Service (IHS). It consolidates procurement, allowing for bulk purchasing and potentially better inventory management. For remote facilities, a reliable prime vendor ensures consistent access to a broad formulary without each facility needing to manage individual supplier relationships. However, effectiveness hinges on the vendor's distribution network, logistics capabilities, and responsiveness to the unique needs of remote locations. Challenges can still arise with last-mile delivery, extreme weather, or unexpected demand surges, requiring robust contingency planning by both the IHS and the prime vendor.

What is the typical profit margin for pharmaceutical distributors on federal contracts compared to the commercial market?

Profit margins for pharmaceutical distributors on federal contracts can vary significantly based on the specific contract type, volume, product mix, and competitive landscape. Generally, federal contracts aim for value and cost-effectiveness, which may translate to tighter margins compared to some commercial agreements, especially those involving high-volume, lower-margin generic drugs. However, large IDIQ contracts with established players like McKesson often involve significant volume, which can lead to substantial overall profits even with modest percentage margins. Benchmarking requires comparing the specific terms, product categories, and negotiated discounts against similar commercial contracts and other federal awards. Data on specific profit margins is often proprietary, but the competitive nature of federal procurement generally pushes for efficiency and cost savings.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 6555 STATE HIGHWAY 161, IRVING, TX, 75039

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $9,000,000

Exercised Options: $9,000,000

Current Obligation: $9,000,000

Contract Characteristics

Multi-Year Contract: Yes

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 36W79720D0001

IDV Type: IDC

Timeline